Preventing recurrence of Clostridium difficile infection: bezlotoxumab: Evidence summary [ES13]

This evidence summary discusses two similar randomised controlled trials that compared the efficacy and safety of a single dose of bezlotoxumab 10 mg/kg with placebo for preventing the recurrence of C difficile infection in people taking usual standard-of-care antibiotics (usually metronidazole or vancomycin). A summary to inform local decision-making is included.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news